Mantle cell lymphoma strategies in primary treatment
Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a raredisease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment.This works aimed to (I) investigate outcome in relation to primary treatment in MCL based on population-basedregistry data, (II) to evaluate tolerability and efficacy of lenalidomiMantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. This works aimed to (I) investigate outcome in relation to primary treatment in MCL based on population-based registry data, (II) to evaluate tolerability and efficacy of lenalid